Postpartum Prescription of GLP-1 Drugs Has Increased Sharply, Study Finds
PositiveHealth
- A recent study has revealed a significant increase in the prescription of GLP-1 drugs, particularly among new mothers, with nearly 2 percent receiving these weight-loss medications by mid-2024. Wegovy, a prominent GLP-1 drug, is being packaged at a Novo Nordisk facility in Hillerod, Denmark.
- This surge in prescriptions indicates a growing acceptance and reliance on GLP-1 drugs for postpartum weight management, reflecting a shift in healthcare practices and attitudes towards maternal health and obesity treatment.
- The rise in GLP-1 drug prescriptions coincides with ongoing research aimed at minimizing side effects associated with these medications, such as nausea. Additionally, pharmaceutical companies are exploring new formulations, including oral versions of existing drugs, which could enhance patient compliance and broaden access to effective weight-loss solutions.
— via World Pulse Now AI Editorial System
